Liquidia (LQDA) Set to Announce Earnings on Tuesday

Liquidia (NASDAQ:LQDA - Get Free Report) will release its earnings data before the market opens on Tuesday, May 14th. Analysts expect Liquidia to post earnings of ($0.32) per share for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings results on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.19). Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. The company had revenue of $4.53 million during the quarter, compared to the consensus estimate of $5.29 million. On average, analysts expect Liquidia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Liquidia Stock Down 2.6 %

LQDA traded down $0.34 on Wednesday, reaching $12.50. 594,718 shares of the company traded hands, compared to its average volume of 921,758. The company has a market cap of $954.75 million, a P/E ratio of -10.31 and a beta of 0.24. Liquidia has a one year low of $5.71 and a one year high of $16.99. The firm has a fifty day simple moving average of $14.29 and a two-hundred day simple moving average of $11.63.

Insider Activity

In other news, General Counsel Russell Schundler sold 8,653 shares of the company's stock in a transaction on Monday, March 18th. The stock was sold at an average price of $15.82, for a total transaction of $136,890.46. Following the transaction, the general counsel now directly owns 488,087 shares of the company's stock, valued at $7,721,536.34. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Liquidia news, General Counsel Russell Schundler sold 8,653 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $15.82, for a total value of $136,890.46. Following the completion of the sale, the general counsel now directly owns 488,087 shares in the company, valued at $7,721,536.34. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Roger Jeffs sold 28,583 shares of the business's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $15.82, for a total value of $452,183.06. Following the sale, the chief executive officer now owns 835,345 shares in the company, valued at approximately $13,215,157.90. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 70,999 shares of company stock worth $1,100,444. Corporate insiders own 31.60% of the company's stock.

Wall Street Analyst Weigh In

LQDA has been the subject of a number of research reports. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price target on shares of Liquidia in a report on Wednesday, April 10th. HC Wainwright upped their target price on Liquidia from $16.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).